Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Tetrahydrouridine × Clear all
NCT01534598 2026-02-10

FdCyd and THU for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

NCT00359606 2015-05-06

5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer

City of Hope Medical Center

Phase 1 Completed
58 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡